Blinatumomab - Wikipedia
Blinatumomab, sold under the brand name Blincyto, and known informally as blina, [5] is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
Blinatumomab, a bispecific B-cell and T-cell engaging antibody, …
Blinatumomab (Blincyto, Amgen), a bi-specific antibody, is a first-in-class, targeted immunotherapy agent for treatment of B-cell malignancies with a novel mechanism of action which involves in-vivo engagement of the patient's T cells with CD19-expressing tumour cells.
All about blinatumomab: the bispecific T cell engager …
2024年4月1日 · Blinatumomab is a bispecific T cell engager containing the CD3 and CD19 that recognize domains redirecting cytotoxic T cells to lyse B cells. Promising outcomes, including long-term overall survival and improved MRD-negative response rates, have been reported in patients who received this drug.
FDA approves blinatumomab for acute lymphoblastic leukemia
On June 14, 2024, the FDA approved blinatumomab (Blincyto, Amgen Inc.) for adult and pediatric patients one month and older with CD19-positive Philadelphia chromosome-negative B-cell precursor...
B-Cell Precursor ALL Treatment | BLINCYTO® (blinatumomab)
WHAT IS BLINCYTO ® (blinatumomab)? BLINCYTO ® is a prescription medicine used to treat adults and children 1 month and older with: B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a small number of cancer cells remain in the body (minimal residual disease) ...read more
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia …
2024年7月24日 · The addition of blinatumomab, a bispecific T-cell engager molecule that is approved for the treatment of relapsed, refractory, and MRD-positive BCP-ALL, may have efficacy in patients with MRD ...
Blinatumomab for the Treatment of Adult B-Cell Acute …
2020年2月14日 · Blinatumomab currently carries US Food and Drug Administration (FDA) approvals for the treatment of relapsed/refractory B-cell ALL and minimal/measurable residual disease (MRD)-positive B-cell ALL in adults. Herein, we will review the pharmacology of blinatumomab and the clinical data for its use in these settings.
Blinatumomab versus Chemotherapy for Advanced Acute …
2017年3月2日 · Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts, was approved for...
Efficacy of blinatumomab as maintenance therapy for B-lineage …
2024年7月8日 · The use of prophylactic blinatumomab for high-risk patients who have achieved hematological CR after allo-HSCT is expected to enhance the anti-leukemic effect of engrafted donor-derived CD3 ...
Blinatumomab - NCI - National Cancer Institute
Blinatumomab is approved to treat: B-cell acute lymphoblastic leukemia that is CD19 positive in adults and children aged 1 month and older. It is used: in certain patients with cancer that is in the first or second complete remission; in patients with …